首页> 外文期刊>International Journal of Molecular Sciences >Application of Wnt Pathway Inhibitor Delivering Scaffold for Inhibiting Fibrosis in Urethra Strictures: In Vitro and in Vivo Study
【24h】

Application of Wnt Pathway Inhibitor Delivering Scaffold for Inhibiting Fibrosis in Urethra Strictures: In Vitro and in Vivo Study

机译:Wnt途径抑制剂输送支架在尿道口狭窄中抑制纤维化的应用:体内和体外研究

获取原文
           

摘要

Objective: To evaluate the mechanical property and biocompatibility of the Wnt pathway inhibitor (ICG-001) delivering collagen/poly(l-lactide-co-caprolactone) (P(LLA-CL)) scaffold for urethroplasty, and also the feasibility of inhibiting the extracellular matrix (ECM) expression in vitro and in vivo. Methods: ICG-001 (1 mg (2 mM)) was loaded into a (P(LLA-CL)) scaffold with the co-axial electrospinning technique. The characteristics of the mechanical property and drug release fashion of scaffolds were tested with a mechanical testing machine (Instron) and high-performance liquid chromatography (HPLC). Rabbit bladder epithelial cells and the dermal fibroblasts were isolated by enzymatic digestion method. (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay) and scanning electron microscopy (SEM) were used to evaluate the viability and proliferation of the cells on the scaffolds. Fibrolasts treated with TGF-β1 and ICG-001 released medium from scaffolds were used to evaluate the anti-fibrosis effect through immunofluorescence, real time PCR and western blot. Urethrography and histology were used to evaluate the efficacy of urethral implantation. Results: The scaffold delivering ICG-001 was fabricated, the fiber diameter and mechanical strength of scaffolds with inhibitor were comparable with the non-drug scaffold. The SEM and MTT assay showed no toxic effect of ICG-001 to the proliferation of epithelial cells on the collagen/P(LLA-CL) scaffold with ICG-001. After treatment with culture medium released from the drug-delivering scaffold, the expression of Collagen type 1, 3 and fibronectin of fibroblasts could be inhibited significantly at the mRNA and protein levels. In the results of urethrography, urethral strictures and fistulas were found in the rabbits treated with non-ICG-001 delivering scaffolds, but all the rabbits treated with ICG-001-delivering scaffolds showed wide caliber in urethras. Histology results showed less collagen but more smooth muscle and thicker epithelium in urethras repaired with ICG-001 delivering scaffolds. Conclusion: After loading with the Wnt signal pathway inhibitor ICG-001, the Collagen/P(LLA-CL) scaffold could facilitate a decrease in the ECM deposition of fibroblasts. The ICG-001 delivering Collagen/P(LLA-CL) nanofibrous scaffold seeded with epithelial cells has the potential to be a promising substitute material for urethroplasty. Longer follow-up study in larger animals is needed in the future.
机译:目的:评价Wnt途径抑制剂(ICG-001)递送胶原蛋白/聚(l-丙交酯-己内酯)(P(LLA-CL))支架进行尿道成形术的力学性能和生物相容性,以及抑制其可行性。体外和体内细胞外基质(ECM)的表达。方法:使用同轴电纺丝技术将ICG-001(1 mg(2 mM))装入(P(LLA-CL))支架中。用机械测试仪(Instron)和高效液相色谱法(HPLC)测试支架的机械性能和药物释放方式。采用酶消化法分离兔膀胱上皮细胞和真皮成纤维细胞。 (3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四唑溴化物(MTT)测定)和扫描电子显微镜(SEM)用于评估支架上细胞的活力和增殖。用TGF-β1和ICG-001从支架释放的介质处理的成纤维细胞通过免疫荧光,实时PCR和western blot评估抗纤维化作用。尿道造影和组织学用于评估尿道植入的疗效。结果:制备了递送ICG-001的支架,具有抑制剂的支架的纤维直径和机械强度与非药物支架相当。 SEM和MTT分析表明,ICG-001对胶原蛋白/ P(LLA-CL)支架上的上皮细胞增殖没有毒性作用。用从药物递送支架释放的培养基处理后,成纤维细胞中1、3型胶原和纤连蛋白的表达在mRNA和蛋白质水平上可被显着抑制。在尿道造影的结果中,在用非ICG-001递送支架治疗的兔子中发现了尿道狭窄和瘘管,但是所有用ICG-001递送支架治疗的兔子在尿道中都显示出宽口径。组织学结果显示,用ICG-001输送支架修复的尿道中胶原蛋白较少,但平滑肌更厚,上皮更厚。结论:加载Wnt信号通路抑制剂ICG-001后,胶原蛋白/ P(LLA-CL)支架可以促进成纤维细胞ECM沉积的减少。植入了上皮细胞的ICG-001递送胶原蛋白/ P(LLA-CL)纳米纤维支架,有望成为有希望的尿道成形术替代材料。将来需要对大型动物进行更长的随访研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号